Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6199347 | Ophthalmology | 2015 | 7 Pages |
Abstract
Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for â¥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Michael J. MD, Allison MS, Neil M. MD, David MD, Christina J. MD, Adam R. MS, Lee M. MD, Thomas W. MD, Diabetic Retinopathy Clinical Research Network Diabetic Retinopathy Clinical Research Network,